Medicare Enrolled
Dr. Alan Cutler, MD
Gastroenterology · Farmington Hills, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Cutler from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cutler?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Cutler
Dr. Alan Cutler is a gastroenterology specialist in Farmington Hills, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Cutler performed 10,552 Medicare services across 813 unique beneficiaries.
Between the years covered by Open Payments, Dr. Cutler received a total of $68,842 from 56 pharmaceutical and/or device companies across 923 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Cutler is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in MI
$68,842 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,552
Medicare services
Top 1% in MI for gastroenterology
813
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~528 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
8,700 | $18 | $29 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
920 | $26 | $150 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
230 | $65 | $115 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
132 | $96 | $180 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
64 | $89 | $550 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
58 | $222 | $800 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
55 | $193 | $700 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
53 | $76 | $200 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
52 | $161 | $750 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
51 | $107 | $360 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
45 | $79 | $400 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
42 | $108 | $250 |
| Colonoscopy A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon. |
37 | $153 | $700 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
35 | $42 | $80 |
| Colonoscopy for colorectal cancer screening A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease. |
31 | $194 | $700 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $131 | $300 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
21 | $23 | $100 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
91.7% high complexity
2.9% medium
5.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$68,842
Total received (2018-2024)
Avg $9,835/year across 7 years
Top 2% in MI for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
56
Companies
923
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$50,137 (72.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,935 (23.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,770 (4.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$25,151
2023
$11,994
2022
$14,138
2021
$12,102
2020
$402
2019
$2,583
2018
$2,473
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Phathom Pharmaceuticals, Inc.
$21,823
Takeda Pharmaceuticals U.S.A., Inc.
$610
ABBVIE INC.
$580
Janssen Biotech, Inc.
$543
Lilly USA, LLC
$172
Gilead Sciences, Inc.
$167
PFIZER INC.
$160
Intercept Pharmaceuticals, Inc.
$134
Celgene Corporation
$127
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$120
IRONWOOD PHARMACEUTICALS, INC
$114
Regeneron Healthcare Solutions, Inc.
$104
AIMMUNE THERAPEUTICS, INC.
$78
GENZYME CORPORATION
$68
QOL Medical, LLC
$65
Ipsen Biopharmaceuticals, Inc
$57
Organon Llc
$33
Ferring Pharmaceuticals Inc.
$29
CapsoVision, Inc.
$29
SHIELD THERAPEUTICS INC
$29
Celltrion USA Inc.
$29
Ardelyx, Inc.
$22
Madrigal Pharmaceuticals
$18
AstraZeneca Pharmaceuticals LP
$16
EVOKE PHARMA, INC.
$13
Endogastric Solutions, Inc
$12
Top 3 companies account for 91.5% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$27,341
Phathom Pharmaceuticals, Inc.
$21,836
RedHill Biopharma Inc.
$2,790
Janssen Biotech, Inc.
$2,123
Celgene Corporation
$1,995
Takeda Pharmaceuticals U.S.A., Inc.
$1,726
ABBVIE INC.
$1,264
AbbVie, Inc.
$1,175
Gilead Sciences, Inc.
$1,079
AbbVie Inc.
$960
Allergan Inc.
$896
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$734
PFIZER INC.
$663
Amgen Inc.
$358
Ironwood Pharmaceuticals, Inc
$350
Ferring Pharmaceuticals Inc.
$286
Merck Sharp & Dohme Corporation
$279
GENZYME CORPORATION
$248
UCB, Inc.
$242
Intercept Pharmaceuticals, Inc.
$221
Braintree Laboratories, Inc.
$187
Lilly USA, LLC
$172
Regeneron Healthcare Solutions, Inc.
$170
Synergy Pharmaceuticals Inc
$147
QOL Medical, LLC
$127
INTERCEPT PHARMACEUTICALS, INC.
$125
Janssen Scientific Affairs, LLC
$125
Nestle HealthCare Nutrition Inc.
$118
IRONWOOD PHARMACEUTICALS, INC
$114
Organon LLC
$101
AIMMUNE THERAPEUTICS, INC.
$78
Merck Sharp & Dohme LLC
$77
NESTLE HEALTHCARE NUTRITION INC.
$70
Daiichi Sankyo Inc.
$64
Ipsen Biopharmaceuticals, Inc
$57
Alexion Pharmaceuticals, Inc.
$52
Celltrion USA Inc.
$52
Mylan Institutional Inc.
$38
Ardelyx, Inc.
$35
Welch Allyn
$34
Shionogi Inc
$34
Organon Llc
$33
AstraZeneca Pharmaceuticals LP
$32
CapsoVision, Inc.
$29
SHIELD THERAPEUTICS INC
$29
Shire North American Group Inc
$28
Madrigal Pharmaceuticals
$18
Fresenius Kabi USA, LLC
$17
Concordia Pharmaceuticals Inc.
$17
Prometheus Laboratories Inc.
$16
Ethicon US, LLC
$15
Cook Medical LLC
$14
EVOKE PHARMA, INC.
$13
Sandoz Inc.
$13
Endogastric Solutions, Inc
$12
AMAG Pharmaceuticals, Inc.
$12
Top 3 companies account for 75.5% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · AMJEVITA · ANDEXXA · APRISO · AVSOLA · Amitiza · CIMZIA · CLENPIQ · CREON · CYCLOSET · CapsoCam Plus · Cimzia · Creon · DIFICID · DUPIXENT · Dexilant · Donnatal · ENTYVIO · EOHILIA · ESOPHYX · Entyvio · Epclusa · FERAHEME · GATTEX · GIMOTI · HADLIMA · HUMIRA · HYRIMOZ · Hulio · Humira · IBSRELA · IDACIO · INFLECTRA · INJECTAFER · INSTINCT · IQIRVO · Kanuma · LINZESS · Linzess · MAVYRET · MOTEGRITY · Mavyret · Movantik · OCALIVA · OMVOH · Propaq Monitor · REBYOTA · REMICADE · RENFLEXIS · RESMETIROM · RINVOQ · SKYRIZI · STELARA · SUCRAID · SUPREP · SUPREP BOWEL PREP · SUTAB · Sucraid · Symproic · TALICIA · TREMFYA · TRULANCE · Talicia · Trulance · ULTOMIRIS · VIBERZI · VOQUEZNA · XELJANZ · XIFAXAN · YUFLYMA · ZENPEP · ZEPATIER · ZEPOSIA · ZYMFENTRA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (73%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in gastroenterology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for gastroenterology in MI.
Geographic Context
Gastroenterologists within 10 mi
184
Per 100K population
14.5
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL - FARMINGTON HILLS
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Cutler is a mixed practice specialist, with above-average Medicare volume (top 1% in MI), with speaking/promotional industry engagement in the top 2% of MI peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Cutler experienced with vedolizumab infusion (entyvio)?
Based on Medicare claims data, Dr. Cutler performed 8,700 vedolizumab infusion (entyvio) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Cutler receive payments from pharmaceutical companies?
Yes. Dr. Cutler received a total of $68,842 from 56 companies across 923 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Cutler's costs compare to other gastroenterologists in Farmington Hills?
Dr. Cutler's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Cutler) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Farmington Hills
Browse gastroenterologists in Farmington Hills ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in MI
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in MI
Which MI gastroenterologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Phathom Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Phathom Pharmaceuticals, Inc.
By company
RedHill Biopharma Inc. Payments to Doctors
See all physicians who received payments from RedHill Biopharma Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology